

(FILE 'USPAT' ENTERED AT 11:11:17 ON 09 OCT 1998)

L1	57 S SCID-HU
L2	223 S 800/2/ICLS
L3	15 S L1 AND L2
L4	0 S L3 AND MACROPHAGE DEPLETION
L5	0 S L3 AND DICHLOROMETHYLENE DIPHOSPHONATE
L6	0 S L3 AND (DICHLOROMETHYLENE DIPHOSPHONATE OR DMDP)
L7	36 S DICHLOROMETHYLENE DIPHOSPHONATE OR DMDP
L8	0 S L2 AND L7
L9	0 S L1 AND L7
L10	1 S L7 AND SCID
L11	4 S L7 AND MAMMAL

1. 5,811,635, Sep. 22, 1998, Chimeric mouse for human and mouse immune systems; Harris Goldstein, et al., 424/93.1 [IMAGE AVAILABLE]
2. 5,804,160, Sep. 8, 1998, Animal model for hepatitis virus infection; Yair Reisner, 424/9.1, 141.1, 142.1; 435/70.21 [IMAGE AVAILABLE]
3. 5,709,843, Jan. 20, 1998, Engraftment and development of xenogeneic cells in normal mammals having reconstituted hematopoietic deficient immune systems; Yair Reisner, 424/9.2, 9.1, 93.1, 93.3, 93.7, 93.71, 520; 435/4, 5; 800/9, 11 [IMAGE AVAILABLE]
4. 5,663,481, Sep. 2, 1997, Animal model of the human immune system; Steven Gallinger, et al., 800/11; 424/93.7; 800/18 [IMAGE AVAILABLE]
5. 5,652,373, Jul. 29, 1997, Engraftment and development of xenogeneic cells in normal mammals having reconstituted hematopoietic deficient immune systems; Yair Reisner, 800/11; 424/9.1, 9.2, 93.1, 577; 800/18 [IMAGE AVAILABLE]
6. 5,643,551, Jul. 1, 1997, Small animal metastasis model; Reiko Namikawa, et al., 800/3; 424/9.1, 9.2, 93.1, 93.3, 520, 529, 578, 582, 900 [IMAGE AVAILABLE]
7. 5,639,939, Jun. 17, 1997, Chimeric immunocompromised mammal comprising vascularized fetal organ tissue; Joseph M. McCune, III, 800/11; 424/9.2, 93.7, 549, 553, 577, 578, 579, 580, 582; 623/11 [IMAGE AVAILABLE]
8. 5,633,426, May 27, 1997, In vivo use of human bone marrow for investigation and production; Reiko Namikawa, et al., 800/3; 424/9.2, 93.7, 549, 577, 578, 579, 580, 582; 623/11; 800/11 [IMAGE AVAILABLE]
9. 5,625,127, Apr. 29, 1997, Extended human hematopoiesis in a heterologous host; Hideto Kaneshima, et al., 800/11; 424/9.2, 93.7, 553, 577, 578, 579, 580, 582; 623/11 [IMAGE AVAILABLE]
10. 5,612,018, Mar. 18, 1997, Drug screening and treatment for HIV thymocyte depletion; Mark L. Bonyhadi, et al., 424/9.2, 553, 577, 580, 582 [IMAGE AVAILABLE]
11. 5,583,278, Dec. 10, 1996, Recombination activating gene deficient mouse; Frederick W. Alt, et al., 800/11; 424/9.2, 204.1, 234.1; 435/320.1; 800/18, 24 [IMAGE AVAILABLE]
12. 5,516,977, May 14, 1996, Xenogeneic tissue implant in ear pinna; Brian Ford, et al., 800/11; 424/9.37, 578; 800/18 [IMAGE AVAILABLE]
13. 5,510,099, Apr. 23, 1996, Mutagenesis testing using transgenic non-human animals carrying test DNA sequences; Jay M. Short, et al., 800/3; 424/9.1; 435/317.1, 320.1, 488 [IMAGE AVAILABLE]
14. 5,476,997, Dec. 19, 1995, Extended human hematopoiesis in a heterologous host; Hideto Kaneshima, et al., 800/9; 424/520, 553, 577, 578, 580, 582 [IMAGE AVAILABLE]
15. 5,434,341, Jul. 18, 1995, Xenogeneic lymph node in mammary fat pad; Henry C. Outzen, 800/10; 424/93.7, 553, 578, 580, 582; 800/18 [IMAGE AVAILABLE]

US PAT NO: 5,811,635 [IMAGE AVAILABLE] L3: 1 of 15
DATE ISSUED: Sep. 22, 1998
TITLE: Chimeric mouse for human and mouse immune systems
INVENTOR: Harris Goldstein, Bronx, NY
Tobias R. Kollmann, Bronx, NY
ASSIGNEE: Albert Einstein College of Medicine of Yeshiva University,
a Division of Yeshiva University, Bronx, NY (U.S. corp.)
APPL-NO: 08/739,281
DATE FILED: Oct. 29, 1996
ART-UNIT: 184
PRIM-EXMR: Suzanne E. Ziska
LEGAL-REP: Amster, Rothstein & Ebenstein

US PAT NO: 5,811,635 [IMAGE AVAILABLE] L3: 1 of 15

ABSTRACT:

This invention is directed to a chimeric mouse capable of mounting murine cellular and humoral immune response, said chimeric mouse being tolerant of human tissue implanted therein. The chimeric mouse of this invention is capable of developing murine T cells and producing murine IgG antibodies, which T cells and antibodies are tolerant of the human tissue implanted in said mouse, thereby allowing for the challenge of said vaccinated mouse with human-specific pathogens and determining the capacity of the vaccine to protect the cells in said implanted tissue from infection. This invention is also directed to a method for the development of said chimeric mouse, as well as to the use of said chimeric mouse for the screening of vaccines for human-specific pathogens.

US PAT NO: 5,709,843 [IMAGE AVAILABLE] L3: 3 of 15
DATE ISSUED: Jan. 20, 1998
TITLE: Engraftment and development of xenogeneic cells in normal
mammals having reconstituted hematopoietic deficient
immune systems
INVENTOR: Yair Reisner, Tel Aviv, Israel
ASSIGNEE: Yeda Research and Development Co. Ltd., Rehovot, Israel
(foreign corp.)
APPL-NO: 08/347,088
DATE FILED: Nov. 23, 1994
ART-UNIT: 189
PRIM-EXMR: Brian R. Stanton
LEGAL-REP: Browdy and Neimark

US PAT NO: 5,709,843 [IMAGE AVAILABLE] L3: 3 of 15

ABSTRACT:

Non-human chimeric mammals are created from a mammal having hematopoietic cells replaced with hematopoietic cells from a hematopoietic deficient mammal donor, and optionally in which xenogeneic cells and/or tissue are engrafted. The xenogeneic, preferably human, cells or tissue may be hematopoietic cells, in which case the chimeric mammal can produce xenogeneic B and/or T cells, and can be used as a source of mammalian, preferably human, monoclonal antibodies and/or T cells. Alternatively, the xenogeneic cells or tissue may be non-hematopoietic, such as normal or pathological cells or tissue, which can form a stable transplant in the chimeric mammal and thus can be used as an animal model of various pathologies or to test therapeutic or diagnostic agents or modalities.

US PAT NO: 5,652,373 [IMAGE AVAILABLE] L3: 5 of 15
DATE ISSUED: Jul. 29, 1997
TITLE: Engraftment and development of xenogeneic cells in normal
mammals having reconstituted hematopoietic deficient
immune systems
INVENTOR: Yair Reisner, Tel Aviv, Israel
ASSIGNEE: Yeda Research and Development Co. Ltd., Rehovot, Israel
(foreign corp.)
APPL-NO: 08/061,706
DATE FILED: May 17, 1993
ART-UNIT: 184
PRIM-EXMR: Brian R. Stanton
LEGAL-REP: Brwowydy and Neimark

US PAT NO: 5,652,373 [IMAGE AVAILABLE] L3: 5 of 15

ABSTRACT:

Non-human chimeric mammals are created from a mammal having hematopoietic cells replaced with hematopoietic cells from a hematopoietic deficient mammal donor, and optionally in which xenogeneic cells and/or tissue are engrafted. The xenogeneic, preferably human, cells or tissue may be hematopoietic cells, in which case the chimeric mammal can produce xenogeneic B and/or T cells, and can be used as a source of mammalian, preferably human, monoclonal antibodies and/or T cells. Alternatively, the xenogeneic cells or tissue may be non-hematopoietic, such as normal or pathological cells or tissue, which can form a stable transplant in the chimeric mammal and thus can be used as an animal model of various pathologies or to test therapeutic or diagnostic agents or modalities.

US PAT NO: 5,639,939 [IMAGE AVAILABLE] L3: 7 of 15
DATE ISSUED: Jun. 17, 1997
TITLE: Chimeric immunocompromised mammal comprising vascularized
fetal organ tissue
INVENTOR: Joseph M. McCune, III, San Francisco, CA
ASSIGNEE: The Board of Trustees for the Leland Stanford Junior
University, Palo Alto, CA (U.S. corp.)
APPL-NO: 08/205,053
DATE FILED: Mar. 1, 1994
ART-UNIT: 189
PRIM-EXMR: Jasmine C. Chambers
ASST-EXMR: Jill Schmuck
LEGAL-REP: Pamela J. Fish and Richardson P.C. Sherwood

US PAT NO: 5,639,939 [IMAGE AVAILABLE] L3: 7 of 15

ABSTRACT:

Xenogeneic tissue is introduced into an immunocompromised host for interacting with agents and using such interaction for evaluating efficacy of drugs and vaccines, producing xenogeneic monoclonal antibodies, evaluating the effect of the various agents on specific tissues and the like. Particularly, drugs can be evaluated for their efficacy against a wide variety of pathogens which infect xenogeneic tissue, agents can be evaluated for their effect on the xenogeneic immune system and monoclonal antibodies to a predetermined epitope may be produced.

US PAT NO: 5,633,426 [IMAGE AVAILABLE] L3: 8 of 15
DATE ISSUED: May 27, 1997
TITLE: In vivo use of human bone marrow for investigation and
production
INVENTOR: Reiko Namikawa, Palo Alto, CA

Seiji Kyoizumi, Hiroshima, Japan
Joseph M. McCune, San Francisco, CA
Hideto Kaneshima, Palo Alto, CA
ASSIGNEE: Systemix, Inc., Palo Alto, CA (U.S. corp.)
APPL-NO: 08/194,717
DATE FILED: Feb. 10, 1994
ART-UNIT: 189
PRIM-EXMR: Jasemine C. Chambers
LEGAL-REP: Pamela J. Fish & Richardson P.C. Sherwood

US PAT NO: 5,633,426 [IMAGE AVAILABLE] L3: 8 of 15

ABSTRACT:

Chimeric immunocompromised hosts are provided, comprising human bone marrow of at least 4 weeks from the time of implantation. The bone marrow is found to assume the normal population of bone marrow except for erythrocytes. The bone marrow may be used to study the effect of various agents on the proliferation and differentiation of hematopoietic cells.

US PAT NO: 5,625,127 [IMAGE AVAILABLE] L3: 9 of 15
DATE ISSUED: Apr. 29, 1997
TITLE: Extended human hematopoiesis in a heterologous host
INVENTOR: Hideto Kaneshima, Palo Alto, CA
Reiko Namikawa, Palo Alto, CA
Joseph M. McCune, San Francisco, CA
ASSIGNEE: Systemix, Inc., Palo Alto, CA (U.S. corp.)
APPL-NO: 08/434,706
DATE FILED: May 4, 1995
ART-UNIT: 184
PRIM-EXMR: Jasemine C. Chambers
LEGAL-REP: Pamela J. Fish & Richardson P.C. Sherwood

US PAT NO: 5,625,127 [IMAGE AVAILABLE] L3: 9 of 15

ABSTRACT:

A human hematopoietic system is provided in an immunocompromised mammalian host, where the hematopoietic system is functional for extended periods of time. Particularly, human fetal liver tissue and human fetal thymus is introduced into an appropriate site of a young immunocompromised mouse at a site supplied with a vascular system, whereby the fetal tissue results in novel formation of functional human bone marrow tissue.

US PAT NO: 5,476,997 [IMAGE AVAILABLE] L3: 14 of 15
DATE ISSUED: Dec. 19, 1995
TITLE: Extended human hematopoiesis in a heterologous host
INVENTOR: Hideto Kaneshima, Palo Alto, CA
Reiko Namikawa, Palo Alto, CA
Joseph M. McCune, San Francisco, CA
ASSIGNEE: Systemix, Inc., Palo Alto, CA (U.S. corp.)
APPL-NO: 08/245,250
DATE FILED: May 17, 1994
ART-UNIT: 184
PRIM-EXMR: Jasemine C. Chambers
LEGAL-REP: Bertram I. Rowland, Pamela J. Sherwood

US PAT NO: 5,476,997 [IMAGE AVAILABLE] L3: 14 of 15

ABSTRACT:

A human hematopoietic system is provided in an immunocompromised mammalian host, where the hematopoietic system is functional for extended periods of time. Particularly, human fetal liver tissue and human fetal thymus is introduced into an appropriate site of a young

immunocompromised
whereby the fetal
bone marrow tissue.

se at a site supplied with a vascular system,
sue results in novel formation of functional human

US PAT NO: 5,578,309 [IMAGE AVAILABLE] L10: 1 of 1
DATE ISSUED: Nov. 26, 1996
TITLE: Candida albicans phosphomannoprotein adhesion as a vaccine
INVENTOR: Jim E. Cutler, Bozeman, MT
Yongmoon Han, Bozeman, MT
ASSIGNEE: The Research and Development Institute, Inc., Bozeman, MT
(U.S. corp.)
APPL-NO: 08/483,558
DATE FILED: Jun. 7, 1995
ART-UNIT: 182
PRIM-EXMR: James C. Housel
ASST-EXMR: Ginny Allen Portner
LEGAL-REP: Lowe, Price, LeBlanc & Becker

US PAT NO: 5,578,309 [IMAGE AVAILABLE] L10: 1 of 1

ABSTRACT:

A composition, pharmaceutical composition, vaccine and method for the treatment of disseminated candidiasis due to infection by C. albicans. The composition includes phosphomannoprotein which contains adhesins from C. albicans.